Borussertib, another allosteric pan-AKT inhibitor, was tested in vitro using eight different cancer cell lines, including KU-19-19 bladder cells harboring aberrations in the PI3K/AKT and RAS/MAPK pathways. Here, PIK3CD is linked to cancer.